Queen Elizabeth

DR. JANE GOODALL CELEBRATES HER 90TH BIRTHDAY WITH UPCOMING EVENTS IN CANADA, WORKING TIRELESSLY TO SAFEGUARD THE FUTURE OF THE PLANET

Retrieved on: 
Tuesday, April 2, 2024
Climate change, Environment, ICON, Research, G Adventures, Jane Goodall Institute, Air Canada, Hope, Life, Outline, Glass, Biodiversity loss, Empowerment, Animal, JGI, Queen Elizabeth

At just 26 years old, Jane followed her passion for wildlife to Gombe, Tanzania, where she began her groundbreaking research of wild chimpanzees.

Key Points: 
  • At just 26 years old, Jane followed her passion for wildlife to Gombe, Tanzania, where she began her groundbreaking research of wild chimpanzees.
  • On average, Dr. Goodall travels 300 days per year, speaking about the converging crises of climate change, biodiversity loss, and environmental inequity.
  • An extraordinary evening with Dr. Jane Goodall at the Queen Elizabeth Theatre on April 12, 2024.
  • GIFTS IN HONOUR OF DR. JANE GOODALL

Plan International Canada celebrates CEO Lindsay Glassco's Women of Influence Lifetime Achievement Award ahead of International Women's Day

Retrieved on: 
Tuesday, March 5, 2024
Diamond, International, United Nations Volunteers, Woman, Social change, Influence, Global Affairs Canada, McGill University, Food, Interim, Greater Toronto Area, Lead, Volunteering, Foreign Affairs, Distinguishing, Teaching, Rights, UN, Queen Elizabeth, Care International, Food security, Workforce, International Women's Day, Special Olympics Canada, Social justice, Food and Agriculture Organization, Management

TORONTO, March 5, 2024 /CNW/ - Ahead of International Women's Day, March 8, Plan International Canada is excited to announce that President and CEO Lindsay Glassco is the recipient of this year's Top 25 Women of Influence Lifetime Achievement Award .

Key Points: 
  • TORONTO, March 5, 2024 /CNW/ - Ahead of International Women's Day, March 8, Plan International Canada is excited to announce that President and CEO Lindsay Glassco is the recipient of this year's Top 25 Women of Influence Lifetime Achievement Award .
  • Earlier in her career, she spent a decade with the Government of Canada, including at Foreign Affairs and International Trade Canada (now Global Affairs Canada).
  • Plan International Canada thanks Women of Influence+ for amplifying the indomitable spirit of women in all their diversity who are driving progress and innovation in society and congratulates all of the Top 25 Women of Influence® Awards recipients.
  • On International Women's Day, the organization calls on everyone to invest in the extraordinary potential of young women to lead and thrive.

Cunard Announces New Voyages from September 2025 through January 2027

Retrieved on: 
Tuesday, February 20, 2024
UNESCO, Ship, World Heritage Site, Queen Mary 2, Culture, Transatlantic crossing, Sale, Round trip, Panama Canal, Business development, Holiday, Islands of Africa, Queen Elizabeth, Renaissance, International Date Line, Shipbuilding

VALENCIA, Calif., Feb. 20, 2024 /PRNewswire/ -- Luxury cruise line Cunard has announced new voyages sailing from September 2025 to January 2027 across its iconic fleet of four Queens.

Key Points: 
  • Katie McAlister, President of Cunard, said: "We are incredibly excited to have both Queen Anne and Queen Mary 2 offer full World Voyages in 2026.
  • Queen Elizabeth will sail new Caribbean voyages, from September 2025 until April 2026, ranging from nine to 21 nights.
  • For more information about Cunard or to book a voyage, contact your Travel Advisor, call Cunard at 1-800-728-6273, or visit www.cunard.com .
  • For Travel Advisors interested in further information, please contact your Business Development Manager, visit OneSourceCruises.com or call Cunard at 1-800-528-6273.

ZYUS Strengthens Expertise of Clinical Advisory Committee with the Appointment of Dr. Hance Clarke

Retrieved on: 
Thursday, February 1, 2024
Science, Other Science, Research, Natural Resources, Pharmaceutical, Alternative Medicine, Health, Cannabis, Knowledge, School, Chronic pain, Hospital, Faculty, Patient, FRCPC, Public health, Toronto General Hospital, Advisory Committee, Knowledge translation, Medical school, Entrepreneurship, Queen Elizabeth, Consortium, Assistant, Pain management, Drug development, Risk, Anesthesiology, Toronto Centre, Doctor of Philosophy, University, Committee, Medicine, Pharmaceutical industry

ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.

Key Points: 
  • ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, today announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee.
  • Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care.
  • "We are pleased to announce the appointment of Dr. Hance Clarke to the Clinical Advisory Committee," said Brent Zettl, President and CEO of the Company.
  • This strategic addition to our Clinical Advisory Committee reaffirms ZYUS’ commitment to advancing non-opioid-based therapies as a viable alternative for managing pain.”
    "I am honored to join ZYUS’ Clinical Advisory Committee and eager to contribute to ZYUS’ important work.

Minister St-Onge announces the appointment of Cynthia Price Verreault as the next Chairperson of the Canadian Museum of Immigration at Pier 21

Retrieved on: 
Friday, February 2, 2024
Diamond, Science, Chairperson, The, The Act, Commerce, Pier, Queen Elizabeth, McGill University Health Centre, McGill University, Trustee, Museum, Organization, Furniture

Recently appointed Governor Emerita of McGill University, Ms. Price Verreault has served on several of its advisory committees.

Key Points: 
  • Recently appointed Governor Emerita of McGill University, Ms. Price Verreault has served on several of its advisory committees.
  • The Canadian Museum of Immigration at Pier 21 is a national museum in the Canadian Heritage portfolio.
  • The Canadian Museum of Immigration at Pier 21 is a national museum whose mandate is to enhance public understanding of the experience of immigrants as they arrived in Canada.
  • Under the Act, the Chairperson is appointed by the Minister of Canadian Heritage, with the approval of the Governor in Council.

HEALTH RESEARCH FOUNDATION ANNOUNCES THE RECIPIENTS OF TWO HEALTH RESEARCH AWARDS

Retrieved on: 
Thursday, November 16, 2023
Health equity, Research, Policy, HRF, Deficit spending, Insulin, Medal, Victoria Medal of Honour, Intersectionality, Disease, Nursing, Cumming School of Medicine, Dalhousie University, Patient, Innovative Medicines Canada, University, Equity, IMC, Medal of Honor, Health, Child, Dementia, Rockwood, Ageing, Mental health, Diversity, Quality of life, Frailty, Queen Elizabeth, Medical device, Pharmaceutical industry, Black

He pioneered a way to summarize an older adult's overall health status by counting health deficits in a frailty index which is commonly known as the Rockwood model of frailty.

Key Points: 
  • He pioneered a way to summarize an older adult's overall health status by counting health deficits in a frailty index which is commonly known as the Rockwood model of frailty.
  • Dr. Salami has been involved in over 85 research projects, totalling over $230 million, on various topics, including African immigrant child health, immigrant mental health, and access to healthcare for immigrant children.
  • The Diversity and Equity Research Award recognizes excellence in research by outstanding individuals whose work advances equitable participation in health research and access to health care in Canada and improves the well-being of all residents, particularly those facing inequities.
  • To learn more and stay up to date on Canadian health research, follow the HRF on Twitter and LinkedIn .

Prime Minister announces new Lieutenant Governor for Newfoundland and Labrador

Retrieved on: 
Thursday, October 12, 2023
Assembly, Governor, Lieutenant, Employment, Female, Queen Elizabeth, Public, Queen Elizabeth II Golden Jubilee Medal, Newfoundland and Labrador House of Assembly, Royal assent, Nursing, Crown

OTTAWA, ON, Oct 12, 2023 /CNW/ - The Prime Minister, Justin Trudeau, today announced the appointment of Joan Marie Aylward as the new Lieutenant Governor of Newfoundland and Labrador.

Key Points: 
  • OTTAWA, ON, Oct 12, 2023 /CNW/ - The Prime Minister, Justin Trudeau, today announced the appointment of Joan Marie Aylward as the new Lieutenant Governor of Newfoundland and Labrador.
  • Most recently, Ms. Aylward was Vice-Chair of the Newfoundland and Labrador Labour Relations Board.
  • The Prime Minister thanked the outgoing Lieutenant Governor, the Honourable Judy Foote, for her service to the people of Newfoundland and Labrador and to Canada.
  • Lieutenant Governors are appointed by the Governor General of Canada on the recommendation of the Prime Minister.

BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical Toxicology

Retrieved on: 
Thursday, September 21, 2023
Emergency medicine, CBRN, SERB, Antibody, Palace, International Conference on Emergency Medicine, Ricin, Congress, Queen Elizabeth, International Conference on Information Systems Security and Privacy, Poisoning, Toxicology, Digoxin immune fab, Crotalidae polyvalent immune fab, FDA, Conference, Pharmaceutical industry, Vaccine

West Conshohocken, PA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announced today that SERB will present in vivo data for PR022, a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming North American Congress of Clinical Toxicology (NACCT) in Montreal.

Key Points: 
  • West Conshohocken, PA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announced today that SERB will present in vivo data for PR022, a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming North American Congress of Clinical Toxicology (NACCT) in Montreal.
  • Christon Hill, Chief Innovation Officer, SERB who will be presenting the data, said: “SERB is committed to developing therapies to serve unmet medical needs in the field of toxicology, biodefense, and medical countermeasures.
  • We’re pleased to be presenting our data at this leading clinical toxicology congress about our development of a treatment for ricin poisoning.”
    The company will present neutralization data for 7 doses tested in two murine models of ricin poisoning established by two different Contract Research Organizations using two different ricin batches.
  • Further information about the company’s ricin antidote programme is available to governments, health authorities, and emergency preparedness agencies upon request.

Sierra Leoneans Welcome Newest Mercy Ship, the Global Mercy® into Port of Freetown

Retrieved on: 
Thursday, August 24, 2023
Other Philanthropy, Nursing, Seniors, Managed Care, Men, Family, Other Health, Surgery, Consumer, Optical, Oncology, Teens, Hospitals, Maritime, Transport, Philanthropy, Health, Fund Raising, Foundation, Other Consumer, Queen Elizabeth II Quay, Partnership, Education, Elective surgery, Port, MV Global Mercy, Hope, Multimedia, Government, Anesthesia, Ministry, Queen Elizabeth, Patient, Mercy, Excellency, Ministry of Health (Turkey), System, Mercy Ships, Cleft lip and cleft palate, Demographics of Sierra Leone

President Julius Maada Bio, Freetown has welcomed a Mercy Ships’ hospital ship, marking the sixth instance of the collaboration between Mercy Ships and the government of Sierra Leone.

Key Points: 
  • President Julius Maada Bio, Freetown has welcomed a Mercy Ships’ hospital ship, marking the sixth instance of the collaboration between Mercy Ships and the government of Sierra Leone.
  • This time it is the Global Mercy® the world’s largest non-governmental hospital ship, which has docked at the Queen Elizabeth II Quay.
  • View the full release here: https://www.businesswire.com/news/home/20230823493995/en/
    Sierra Leoneans welcome the Global Mercy.
  • This collaboration with Mercy Ships reflects our vision for a resilient healthcare system in Sierra Leone.

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 20, 2023
Michael G. DeGroote School of Medicine, Drug development, Therapy, Research, CCCC, Bladder cancer, Genentech, Chemistry, National Cancer Institute, Queen Elizabeth, McMaster University, Patient, Queen Elizabeth II Health Sciences Centre, Astellas Pharma, Sanofi, FDA, Breast cancer, Disease, Pharmaceutical industry, Dalhousie

WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Leonard (Len) Reyno, M.D., as chief medical officer, effective July 10, 2023. Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials. At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.

Key Points: 
  • Dr. Reyno is a seasoned biotech executive with nearly 30 years of clinical development experience, spanning first-in-human studies to Phase IV clinical trials.
  • At C4T, Dr. Reyno will be responsible for driving C4T’s clinical strategy to advance its promising pipeline of degrader therapies.
  • “We look forward to leveraging Len’s track record of advancing novel oncology therapeutics to patients, deep strategic and operational experience in clinical development and organizational leadership capabilities,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
  • Prior to Pionyr, he was executive vice president and chief medical officer at ORIC Pharmaceuticals, leading their first product candidate into human trials.